HAYWARD, Calif.--(BUSINESS WIRE)--Feb. 19, 2020--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced plans to participate in the upcoming Cowen Health Care Conference in Boston, Massachusetts.
Management is scheduled to present Tuesday, March 3, 2020 at 9:20am ET. Interested parties may access a live and recorded webcast on the “Investors” section of the company’s website at www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. As a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. Subject to regulatory approval, the initial commercial use is expected to be in the clearance of common and difficult-to-treat skin lesions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that could lead to greater overall satisfaction.
Pulse Biosciences, CellFX and Nano-Pulse Stimulation are registered trademarks of Pulse Biosciences, Inc.
Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation (NPS) technology are for investigational use only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005964/en/
Source: Pulse Biosciences, Inc.
Sandra Gardiner, EVP and CFO
Philip Trip Taylor
Nadine D. Tosk